Cortisol abnormal Trials in Disease

Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion

This trial is investigating whether a medication called Metycor, which contains the active ingredient metyrapone, can help patients with mild autonomous cortisol secretion. This condition occurs when the adrenal glands produce too much cortisol without the normal control mechanisms that usually regulate hormone production.

Main focus: The study aims to determine whether treatment with Metycor over six months can improve health conditions linked to excess cortisol, including high blood pressure, problems with blood sugar regulation, and elevated cortisol levels. Researchers will monitor participants throughout the treatment period to assess changes in these health markers, as well as other factors such as weight, cholesterol levels, and overall quality of life.

Who can participate: The trial is open to adults aged 18 years and older who have been diagnosed with mild autonomous cortisol secretion and experience at least one complication related to metabolism, bone health, or mental health. Participants must also be candidates for surgical removal of one or both adrenal glands if needed. All participants must provide informed consent and be willing to follow the study procedures and attend follow-up appointments.

Who cannot participate: The trial excludes patients with severe, unstable health conditions, individuals who are pregnant or breastfeeding, and those who have recently participated in another clinical trial. People with allergies to the study medication, a history of drug or alcohol abuse, or mental health conditions that might interfere with participation are also not eligible. Additionally, anyone unable to follow study procedures or with medical conditions that the study doctor believes could interfere with the trial will be excluded.

Investigational drug: Metycor is a cortisol synthesis inhibitor that works by blocking an enzyme in the adrenal glands responsible for cortisol production. It is given as 250 mg soft capsules taken orally. The trial will evaluate whether this medication can effectively manage high blood pressure, improve glucose metabolism, and regulate cortisol levels in patients over a six-month treatment period. The study also aims to identify which patients might benefit from surgical treatment of the adrenal glands.